Results 231 to 240 of about 144,316 (318)

Over eight years of transfusion independence with continuous erythropoietin receptor activator and Roxadustat in transfusion-dependent low-risk myelodysplastic syndrome. [PDF]

Oxf Med Case Reports
Ikenoue T, Furumatsu Y, Kitamura T.
europepmc   +1 more source

Comparative effectiveness of darbepoetin vs other agents in chronic kidney disease-related anemia: a systematic review and network meta-analysis. [PDF]

BMC Nephrol
Hassan MF, Bin Faheem MS, Cheema S, Henna F, Javid S, Islam MR, Habib I, Usman M, Kurmasha YH, Samadi S, Mohammad YN.   +10 more
europepmc   +1 more source

Effect of 2-h hypoxic exposure on resting hepcidin levels in young adults. [PDF]

Physiol Rep
Lin CA, Naruse M, Tomiishi C, Matsudo H, Badenhorst CE, Goto K.   +5 more
europepmc   +1 more source

Comparison of administration of oral versus Infusions intravenous iron therapy in diabetic patients with chronic kidney disease receiving Erythropoietin. [PDF]

Pak J Med Sci
Din N, Durrani A, Nouman MK, Haider B.
europepmc   +1 more source

Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I

, 2004
Murat Digicaylioglu, Gwenn A. Garden, Sonia Timberlake, Lauren Fletcher, Stuart A. Lipton   +4 more
openalex   +1 more source

"Live high-train low" induced changes in hemoglobin mass and the erythropoietin-erythroferrone-hepcidin axis in female endurance athletes. [PDF]

Physiol Rep
Kuorelahti T, Ihalainen JK, Linnamo V, Badenhorst C, Kettunen O, Mikkonen R.   +5 more
europepmc   +1 more source

Postnatal erythropoietin treatment mitigates neural cell loss after systemic prenatal hypoxic-ischemic injury

, 2010
Marcus D. Mazur, Robert H. Miller, Shenandoah Robinson   +2 more
openalex   +2 more sources

Expert opinion on the management of anemia in prostate cancer patients receiving PARP inhibitors. [PDF]

Can Urol Assoc J
Hanna L, O'Dwyer R, Hamilou Z, Noonan K, Doucette S, Sridhar SS.   +5 more
europepmc   +1 more source

Ginsenoside Rb1 attenuates erythropoietin-exacerbated vascular calcification in chronic kidney disease through BMP2-dependent Smad1/5/9 inhibition. [PDF]

Cytojournal
Li X, Xu Z, Li Y, Luo Y, Zhou J, Zuo D, Xiong W.   +6 more
europepmc   +1 more source

Rethinking EPO: A Paradigm Shift in Oncology? [PDF]

Cancers (Basel)
Ferrero JM, Mograbi B, Bouriga R, Gal J, Milano G.   +4 more
europepmc   +1 more source